Epidiolex is a cannabis-based drug that is indicated for the treatment of epilepsy associated with Lennox-Gastaut Syndrome or Dravet Syndrome in children over 2 years of age and adults.
This drug has already been approved in the United States by the FDA, being not only the first cannabis-based drug approved in this country, but the first drug to be approved for the treatment of Dravet Syndrome.
Despite being produced from cannabis, this drug has no psychoactive properties, because the substance in its composition is cannabidiol and not tetrahydrocannabinol, molecule responsible for the hallucinogenic effects of marijuana. Learn about the major side effects of marijuana.
How to use
The recommended starting dose is 2.5 mg per kg body weight, 2 times a day, orally. After the first week of treatment, the dose may be increased to 5 mg per kg body weight 2 times daily. The recommended maximum daily dose of Epidiolex is 20 mg / kg per day.
In patients with hepatic impairment, a dose adjustment should be made.
Who should not use
This medication should not be used by people who have hypersensitivity to any of the components of the formula.
In addition, it should be used with caution in people with hepatic insufficiency.
Possible side effects
The most common side effects that can occur with Epidiolex are drowsiness, decreased appetite, diarrhea, increased liver transaminases, fatigue, malaise, skin reactions, insomnia, sleep disorders and infections.
